Clinical Trials Directory

Trials / Completed

CompletedNCT02519751

New Method Using Deuterium Labelled Creatine to Measure Total Body Skeletal Muscle Mass

Total Body Skeletal Muscle Mass Estimation by Creatine (Methyl-d3) Dilution in Athletes

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
20 (actual)
Sponsor
GlaxoSmithKline · Industry
Sex
All
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

Creatine (methyl-d3) dilution (D3-creatine) is a novel technique for the estimation of muscle mass. The method uses a dose of deuterium-labelled creatine to determine total skeletal muscle mass via estimation of total body creatine pool size.The aim of this study is to compare estimates of total body skeletal muscle mass by D3-creatine dilution method and whole body Magnetic Resonance Imaging (MRI) in an athletic population.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTD3 CreatineOne dose of D3 Creatine (60mg capsule) given orally on Day 1
DIETARY_SUPPLEMENTCreatineParticipants will consume an individual dosed level of creatine, based on their estimated muscle mass in doses of 0.03, 0.035, 0.04, 0.045 g.kg.Lean mass/day, increasing on a weekly basis. Final dose of 0.05 g.kg.Lean mass/day is then maintained throughout the study.

Timeline

Start date
2014-10-01
Primary completion
2015-01-01
Completion
2015-01-01
First posted
2015-08-11
Last updated
2015-08-11

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT02519751. Inclusion in this directory is not an endorsement.